The archive
484 stories, newest first — page 4 of 21.
Endocrinology & Metabolism
ACHIEVE-5 reports better glycemic control and weight outcomes without more hypoglycemia when oral orforglipron is added to titrated insulin glargine, but the numerical results are essential to judge clinical value.
Dr. Abu Bakar · 6 min read
Neurology
In a randomized trial, ecopipam reduced tic severity versus placebo in young people with Tourette syndrome, with tolerability that supports further evaluation of dopamine D1 blockade.
Dr. Abu Bakar · 7 min read
Innovation & Devices
A Class I recall covers more than 20,000 US Luna G3 APAP devices running firmware G3-2.00.76. Sleep clinics and DME teams need a closed-loop process to identify affected units and coordinate follow-up.
Rayan Salih · 6 min read
Women's Health
FDA approval makes an emerging ESR1 mutation actionable during aromatase-inhibitor plus CDK4/6-inhibitor therapy for eligible patients with advanced breast cancer.
Rayan Salih · 6 min read
Innovation & Devices
Two phase 3 trials found fewer moderate or severe COPD exacerbations with tozorakimab in current and former smokers, but candidate selection remains unsettled.
Rayan Salih · 6 min read
Endocrinology & Metabolism
SELECT found fewer major cardiovascular events with semaglutide among adults with overweight or obesity, established cardiovascular disease and no diabetes.
Rayan Salih · 6 min read
Innovation & Devices
The FDA classified the Halyard IV START KIT NONSTERILE recall as Class I. Facilities holding affected kits need rapid inventory control and a safe plan for uninterrupted vascular access.
Rayan Salih · 6 min read
Innovation & Devices
An FDA Class 2 recall addresses possible positioning-arm detachment in affected PiCardia ShortCut transfemoral catheters. Structural heart programs should reconcile inventory, procedure plans and prior use.
Rayan Salih · 6 min read
Oncology
Accelerated approval covers previously treated advanced nonsquamous NSCLC with qualifying HER2 tyrosine-kinase-domain activating mutations confirmed by an FDA-approved test.
Rayan Salih · 6 min read
Oncology
The FDA approved lirafugratinib for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring an eligible FGFR2 fusion or rearrangement.
Rayan Salih · 7 min read
Cardiology
American Regent recalled one lot of papaverine hydrochloride injection because of glass and/or paraformaldehyde particles, prompting stock quarantine, administration tracing and postexposure review.
Rayan Salih · 6 min read
Oncology
The FDA granted accelerated approval to sevabertinib for a biomarker-defined group of adults with locally advanced or metastatic non-squamous NSCLC. The exact label governs testing and treatment-line eligibility.
Rayan Salih · 7 min read
Oncology
ASTRUM-006 found an event-free survival benefit from adding serplulimab to perioperative SOX in PD-L1-positive, resectable gastric or gastroesophageal junction adenocarcinoma.
Rayan Salih · 7 min read
Clinical Briefs
Randomized comparative evidence favors fecal microbiota transplantation over vancomycin or fidaxomicin for selected adults with recurrent C. difficile infection, particularly after multiple recurrences.
Rayan Salih · 6 min read
Clinical Briefs
The 2026 universal definition gives emergency, outpatient and inpatient teams a shared framework for identifying heart failure, but local rules must still address coding, referrals and program eligibility.
Rayan Salih · 7 min read
Clinical Briefs
A nationwide recall of 0.9% sodium chloride injection requires US hospitals, pharmacies and infusion services to quarantine affected lots and coordinate safe replacement supply.
Dr. Abu Bakar · 6 min read
Infectious Disease
CDC reported recalls by at least three Texas pharmacies after adverse events linked to compounded injectable glutathione. Clinicians should trace recalled products and report suspected reactions.
Dr. Abu Bakar · 6 min read
Mental & Behavioral Health
A pragmatic randomized trial found that mirtazapine reduced methamphetamine use in adults with methamphetamine use disorder, with reported safety findings supporting further evaluation in routine care.
Dr. Abu Bakar · 6 min read
Clinical Briefs
A nationwide cohort associated SGLT2 inhibitors with lower heart-failure hospitalization and all-cause mortality risks than DPP-4 inhibitors or sulfonylureas in HFpEF and type 2 diabetes.
Dr. Abu Bakar · 6 min read
Innovation & Devices
A meta-analysis brings together 11 randomized trials involving 1,614,689 participants, but wide clinical variation limits what can be inferred about cardiovascular AI as a single category.
Dr. Abu Bakar · 6 min read
Infectious Disease
A 2026 meta-analysis found no broad mortality, clinical-response, or microbiological-response advantage for newer antibiotics over generic comparators in bacterial infections.
Dr. Abu Bakar · 6 min read
Innovation & Devices
An FDA Class I recall covers Luna G3 APAP model LG3600 with specified firmware. Clinicians and suppliers need to identify exposed patients and protect continuity of positive airway pressure therapy.
Rayan Salih · 6 min read
Innovation & Devices
Certain ResMed Astral 100 and 150 ventilators require correction because supercapacitor leakage may contribute to failure. Ventilator-dependent patients need prompt device checks and reliable backup plans.
Rayan Salih · 6 min read
Endocrinology & Metabolism
The Endocrine Society advises against routine brain MRI for girls ages 6–8 and boys ages 8–9 with central precocious puberty and no neurologic signs.
Rayan Salih · 6 min read